Trastuzumab, Bevacizumab with Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy

This study is testing a combination of three drugs — trastuzumab (Herceptin), bevacizumab, and paclitaxel — as a second-line treatment for people with HER2-positive advanced stomach cancer whose cancer has progressed after initial therapy. **You may be eligible if...** - You have HER2-positive advanced gastric (stomach) cancer, confirmed by lab testing - Your cancer has gotten worse after one prior treatment for advanced disease - You are 19 years or older - Your overall health is good enough to receive treatment (ECOG 0, 1, or 2) - Your blood counts, liver, and kidney function are within acceptable ranges - You have measurable cancer lesions on imaging **You may NOT be eligible if...** - Your HER2 status is negative or unknown - You have not yet received any treatment for your advanced cancer - You have had more than one prior treatment line for advanced disease - Your organ function is too poor to tolerate the treatment - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.